1IA
BCRX icon

1620 Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

1620 Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,180
Closed -$11.2K – 679
2026
Q1 		$11.2K Buy
+1,180
New +$9.16K 0.01% 458

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

1620 Investment Advisors's BCRX Position: Q2 2026 in Review

1620 Investment Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 1,180 shares — an estimated $11.2K sold.

1620 Investment Advisors first reported a position in BCRX in Q1 2026 and held it in 1 quarter. The position peaked at $11.2K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • 1620 Investment Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • 1620 Investment Advisors sold 1,180 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $11.2K.
  • 1620 Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • 1620 Investment Advisors's BioCryst Pharmaceuticals position peaked at $11.2K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.